Rare Diseases Today—June 25, 2026

This week’s Rare Diseases update highlights regulatory milestones, clinical-development progress, access initiatives, manufacturing collaborations, and strategic advances across multiple rare disease programs.

In Today’s Newsletter

Dive deeper

🧬 Prime Medicine PM359 RMAT designation [1] [US • 22 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/22/3315247/0/en/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-pm359-for-the-treatment-of-chronic-granulomatous-disease-cgd.html
Context: PM359 is an investigational autologous Prime Edited hematopoietic stem cell therapy for p47phox-deficient CGD.
Key point: FDA granted RMAT designation based on Phase 1/2 data, including results previously published in NEJM.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Jaguar Health explores strategic alternatives for crofelemer [2] [US • 22 Jun 2026]

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-plan-to-explore-strategic-alternatives-aligne-1179969
Context: Crofelemer is being developed for rare intestinal failure diseases, including MVID and SBS-IF.
Key point: Jaguar Health initiated a strategic review aligned with anticipated clinical work supporting a targeted NDA filing.
Implication: Signals pipeline investment and modality expansion.

🩸 Sanofi Wayrilz approved in Japan for ITP [3] [Japan • 23 Jun 2026]

https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-23-05-15-00-3315701
Context: Wayrilz (rilzabrutinib) is an oral reversible BTK inhibitor evaluated in LUNA 3 Phase 3.
Key point: Japan approved Wayrilz for persistent or chronic ITP after insufficient response or tolerability issues with other treatments.
Implication: May influence prescriber choice and payer reviews pending full data.

🇰🇷 Novo Nordisk Korea highlights rare disease access [4] [Korea • 19 Jun 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=32107
Context: Novo Nordisk Korea focuses on rare blood disorders and rare endocrine diseases, including hemophilia and growth hormone deficiency.
Key point: The company emphasized access, real-world evidence, patient education, and once-weekly Sogroya reimbursement in Korea.
Implication: May expand screening, initiation, and follow-up at scale.

🏭 SK pharmteco and OTXL form rare disease manufacturing pact [5] [US • 18 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/18/3314253/0/en/sk-pharmteco-announces-strategic-collaboration-with-orphan-therapeutics-accelerator-for-the-development-and-manufacturing-of-rare-disease-therapies.html
Context: Orphan Therapeutics Accelerator focuses on stalled rare disease treatments and access pathways.
Key point: SK pharmteco will serve as preferred technical partner, with prioritized access and preferential rates for up to two programs per year.
Implication: Signals pipeline investment and modality expansion.

❤️ Cadrenal plans tecarfarin rare pediatric disease request [6] [US • 18 Jun 2026]

https://www.contemporarypediatrics.com/view/cadrenal-plans-fda-rare-pediatric-disease-request-for-tecarfarin-in-kawasaki-dis
Context: Tecarfarin is an oral vitamin K antagonist proposed for children with Kawasaki disease and coronary aneurysms.
Key point: Cadrenal plans to seek FDA Rare Pediatric Disease Designation, but no Kawasaki disease efficacy or safety data were reported.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 GRI Bio wins FDA orphan drug designation for GRI-0621 [7] [US • 18 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/18/3314182/0/en/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathic-pulmonary-fibrosis.html
Context: GRI-0621 (tazarotene) is a once-daily oral RARβ/γ-selective investigational therapy for IPF.
Key point: FDA granted orphan drug designation after a Phase 2a trial in 35 IPF patients met reported endpoints.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Yuhan YH35995 gains EMA orphan drug designation [8] [EU • 23 Jun 2026]

https://www.koreabiomed.com/news/articleViewAmp.html?idxno=32138
Context: YH35995 is an oral glucosylceramide synthase inhibitor for Gaucher disease, including potential Type 3 use.
Key point: EMA orphan drug designation follows FDA orphan status and early clinical data presentation.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Regulatory designations remain a key rare disease accelerator, especially for PM359, GRI-0621, tecarfarin, and YH35995.
Japan’s Wayrilz approval adds a BTK inhibitor option for ITP patients with inadequate response or tolerability limits.
Manufacturing access is emerging as a development bottleneck for rare disease programs, reflected in the SK pharmteco–OTXL pact.
Access and adherence are central themes in Korea, especially for hemophilia and growth hormone therapy.
Several programs remain early or investigational, so clinical impact depends on full datasets, trial design, and regulatory feedback.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What did FDA RMAT designation mean for Prime Medicine PM359?

RMAT designation gives PM359 access to intensive FDA interaction and potential expedited review pathways. PM359 is for p47phox-deficient chronic granulomatous disease. [1]

What is Wayrilz (rilzabrutinib) approved for in Japan?

Wayrilz is approved in Japan for persistent or chronic immune thrombocytopenia in patients who do not respond sufficiently to other treatments or have tolerability concerns. [3]

What did Yuhan gain from EMA orphan drug designation for YH35995?

The EMA designation may provide incentives such as scientific advice, reduced regulatory fees, and up to 10 years of EU market exclusivity after approval. [8]

Is tecarfarin approved for Kawasaki disease?

No. Cadrenal plans to request FDA Rare Pediatric Disease Designation for tecarfarin in pediatric Kawasaki disease with coronary aneurysms, but no efficacy or safety data in that population were reported. [6]

What is SK pharmteco doing with Orphan Therapeutics Accelerator?

SK pharmteco will provide technical and manufacturing support to OTXL, including process development, analytical development, and GMP manufacturing support. [5]

Entities / Keywords

Prime Medicine, PM359, Prime Editing, chronic granulomatous disease, CGD, p47phox-deficient CGD, RMAT, FDA.
Jaguar Health, crofelemer, rare intestinal failure, microvillus inclusion disease, MVID, short bowel syndrome intestinal failure, SBS-IF, NDA.
Sanofi, Wayrilz, rilzabrutinib, BTK inhibitor, BTKi, immune thrombocytopenia, ITP, LUNA 3, Japan MHLW.
Novo Nordisk Korea, NovoSeven RT, eptacog alfa, Norditropin, somatropin, Sogroya, hemophilia, growth hormone deficiency, Noonan syndrome.
SK pharmteco, Orphan Therapeutics Accelerator, OTXL, CDMO, GMP manufacturing, rare disease manufacturing.
Cadrenal Therapeutics, tecarfarin, Kawasaki disease, coronary artery aneurysms, Rare Pediatric Disease Designation, oral vitamin K antagonist.
GRI Bio, GRI-0621, tazarotene, idiopathic pulmonary fibrosis, IPF, orphan drug designation, RARβ/γ-selective agonist.
Yuhan Corp., YH35995, Gaucher disease, Type 3 Gaucher disease, glucosylceramide synthase, GCS inhibitor, EMA, FDA orphan drug designation.